ABNORMAL MUCOCILIARY TRANSPORT IN ALLERGIC PATIENTS WITH ANTIGEN-INDUCED BRONCHOSPASM - ROLE OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS

Publisher Website
Google Scholar
Abstract
The possible role of slow reacting substance of anaphylaxis (SRS-A) in mediating mucociliary dysfunction in allergic asthma was evaluated. In 6 asymptomatic nonsmokers with ragweed asthma, specific airway conductance (SGaw) and tracheal mucous velocity (TMV) were measured before and after bronchial challenge with ragweed extract, with or without pretreatment with 0.5 and 1% FPL 55712 [7-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid monosodium salt] (SRS-A antagonist). Mean baseline TMV was 8.9 mm/min (SD, 1.1). Placebo and FPL 55712 per se had no effect on TMV. With placebo pretreatment, the doses of ragweed extract that resulted in a decrease in SGaw by > 35% from baseline led to an immediate decrease in TMV to 74% of baseline, returning to baseline within 2 h. With 0.5 and 1% FPL 55712 pretreatment, doses of ragweed extract that resulted in a similar decrease in SGaw led to an increase in TMV to 130 and 126% of baseline, respectively, immediately after antigen challenge and returned to baseline 2 h postchallenge. Inhalation of 1% FPL 55712 immediately after antigen challenge prevented the decrease in TMV. SRS-A liberated during airway anaphylaxis apparently impairs mucous transport, and the antigen-induced increase in TMV after pretreatment with an SRS-A antagonist may reflect a stimulatory effect of other chemical mediators of anaphylaxis.

This publication has 0 references indexed in Scilit: